A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes
Open Access
- 28 April 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (6) , 1204-1214
Abstract
Based on the 7-year experience of the Italian Clinical Network for FSHD, we revised the FSHD clinical form to describe, in a harmonized manner, the phenotypic spectrum observed in FSHD. The new Comprehensive Clinical Evaluation Form (CCEF) defines various clinical categories by the combination of different features. The inter-rater reproducibility of the CCEF was assessed between two examiners using kappa statistics by evaluating 56 subjects carrying the molecular marker used for FSHD diagnosis. The CCEF classifies: (1) subjects presenting facial and scapular girdle muscle weakness typical of FSHD (category A, subcategories A1–A3), (2) subjects with muscle weakness limited to scapular girdle or facial muscles (category B subcategories B1, B2), (3) asymptomatic/healthy subjects (category C, subcategories C1, C2), (4) subjects with myopathic phenotype presenting clinical features not consistent with FSHD canonical phenotype (D, subcategories D1, D2). The inter-rater reliability study showed an excellent concordance of the final four CCEF categories with a κ equal to 0.90; 95 % CI (0.71; 0.97). Absolute agreement was observed for categories C and D, an excellent agreement for categories A [κ = 0.88; 95 % CI (0.75; 1.00)], and a good agreement for categories B [κ = 0.79; 95 % CI (0.57; 1.00)]. The CCEF supports the harmonized phenotypic classification of patients and families. The categories outlined by the CCEF may assist diagnosis, genetic counseling and natural history studies. Furthermore, the CCEF categories could support selection of patients in randomized clinical trials. This precise categorization might also promote the search of genetic factor(s) contributing to the phenotypic spectrum of disease.Keywords
Funding Information
- Telethon Italy (GUP13012)
- Association Française contre les Myopathies (16593)
- Regione Emilia Romagna (RARER)
This publication has 23 references indexed in Scilit:
- Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1–3 D4Z4 reduced alleles: experience of the FSHD Italian National RegistryBMJ Open, 2016
- Milder phenotype in facioscapulohumeral dystrophy with 7–10 residual D4Z4 repeatsNeurology, 2015
- Facioscapulohumeral Muscular Dystrophy: More Complex than it AppearsCurrent Molecular Medicine, 2014
- Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2Human Molecular Genetics, 2014
- Large scale genotype–phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophyBrain, 2013
- Large-Scale Population Analysis Challenges the Current Criteria for the Molecular Diagnosis of Fascioscapulohumeral Muscular DystrophyThe American Journal of Human Genetics, 2012
- A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical scoreMuscle & Nerve, 2010
- Lung and respiratory muscle function in facioscapulohumeral muscular dystrophyMuscle & Nerve, 2009
- Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD)Human Molecular Genetics, 1995
- Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophyNature Genetics, 1992